Xponance Inc. Increases Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Xponance Inc. increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 9.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,785 shares of the company’s stock after buying an additional 155 shares during the period. Xponance Inc.’s holdings in Krystal Biotech were worth $280,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Cibc World Markets Corp purchased a new stake in shares of Krystal Biotech in the fourth quarter valued at about $364,000. Commonwealth Equity Services LLC lifted its stake in Krystal Biotech by 4.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company’s stock valued at $762,000 after buying an additional 190 shares in the last quarter. Swiss National Bank lifted its stake in Krystal Biotech by 8.4% in the 4th quarter. Swiss National Bank now owns 42,400 shares of the company’s stock valued at $6,642,000 after buying an additional 3,300 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Krystal Biotech by 31.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,054 shares of the company’s stock valued at $948,000 after buying an additional 1,440 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC increased its position in Krystal Biotech by 18.3% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,420 shares of the company’s stock worth $222,000 after buying an additional 220 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital lifted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Finally, Citigroup increased their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $220.00.

Insiders Place Their Bets

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.

Krystal Biotech Trading Down 2.3 %

Shares of KRYS opened at $182.75 on Friday. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34. The firm has a market capitalization of $5.26 billion, a P/E ratio of 61.12 and a beta of 0.87. The stock’s fifty day simple moving average is $170.11 and its 200 day simple moving average is $173.84.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue was up 116.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.30 EPS. Sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).